EVOFEM BIOSCIENCE INC - EVFM STOCK NEWS

Evofem Biosciences, Inc. (NASDAQ: EVFM) has launched its "Get Phexxi" direct-to-consumer campaign to raise awareness about Phexxi®, a non-hormonal birth control method approved by the FDA in May 2020. The campaign addresses the 21 million women in the U.S. at risk for pregnancy who are not using hormonal contraception. The initiative, launched on Valentine's Day, aims to educate women on Phexxi's benefits as an on-demand contraceptive. The campaign includes a national TV commercial and a targeted digital marketing strategy, responding to frustrations expressed by women regarding existing birth control methods.

Evofem Biosciences (NASDAQ: EVFM) and NCODA have partnered to enhance awareness of Phexxi®, a non-hormonal contraceptive, among female cancer patients. This collaboration, initiated on World Cancer Day, aims to provide resources and educational materials for oncology teams to support patients in selecting the best contraceptive options. With over 800,000 new cancer cases reported annually in women in the U.S., the need for non-hormonal options like Phexxi, approved in May 2020, is critical as many cancer treatments necessitate birth control use.

Evofem Biosciences, Inc. (NASDAQ: EVFM) announced its participation in the Medicaid National Drug Rebate Program, effective January 1, 2021. This agreement allows access to Phexxi® (lactic acid, citric acid, and potassium bitartrate) for Medicaid recipients, ensuring equitable contraceptive options for women. Approximately 69.8 million individuals are covered by Medicaid in the U.S., with around 25 million being adult women. The Medicaid Drug Rebate Program aims to reduce costs for outpatient prescription drugs for Medicaid patients, with broad participation from manufacturers.

Evofem Biosciences (NASDAQ: EVFM) announced its participation in the H.C. Wainwright BIOCONNECT 2021 Virtual Conference on December 21, 2020. CEO Saundra Pelletier will discuss the commercialization of Phexxi®, the first FDA-approved hormone-free contraceptive vaginal gel, and provide updates on the ongoing EVOGUARD Phase 3 trial. This trial evaluates EVO100 in preventing chlamydia and gonorrhea. The presentation will be available for on-demand listening starting January 11, 2021, at 6:00 AM Eastern on the company's website under the Events and Presentations tab.

Evofem Biosciences (NASDAQ: EVFM) announced progress in its Phase 3 trial, EVOGUARD, evaluating EVO100 for preventing chlamydia and gonorrhea. Launched in October 2020, enrollment exceeded targets amid COVID-19 challenges. Inbound interest from study centers doubled expectations, with one-third operational by year-end. If successful, EVO100 could offer a new preventive method, following the positive AMPREVENCE trial, showing a 50% reduction in chlamydia and 78% for gonorrhea. EVO100 holds Fast Track and QIDP designations from the FDA.

Evofem Biosciences (NASDAQ: EVFM) announced the listing of two U.S. patents for its contraceptive product, Phexxi®, in the FDA's Orange Book. Phexxi, the first FDA-approved non-hormonal vaginal gel for contraception, was approved in May 2020. The listed patents include the '855 patent, which covers contraception methods and expires in March 2033, and the '276 patent, a composition patent expiring in March 2026. CEO Saundra Pelletier highlighted this listing as a crucial step in expanding their patent portfolio and securing the product's market position.

Evofem Biosciences (NASDAQ: EVFM) has secured a five-year contract from the U.S. Department of Veterans Affairs to supply Phexxi®, a hormone-free contraceptive gel, starting December 15, 2020. This contract expands access to Phexxi for approximately 12 million lives, including patients in VA, Tricare, and other government health programs. The company has achieved coverage for 55% of commercial lives in the U.S., with nearly 8 million lives available at zero copay. This milestone marks a significant step in Evofem's mission to broaden access to women's reproductive health solutions.

Evofem Biosciences (NASDAQ: EVFM) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 30 to December 3, 2020. A pre-recorded fireside chat featuring CEO Saundra Pelletier will be available on November 23 at 10:00 AM Eastern Time. The chat can be accessed on the company's website under the Events and Presentations section. Evofem focuses on women's sexual and reproductive health, with its product, Phexxi®, being the first hormone-free vaginal gel approved in the U.S. for pregnancy prevention.